BioProject

Actinoplanes sp. SE50/110 is known as the wild type producer of the ?-glucosidase inhibitor acarbose, a potent drug used worldwide in the treatment of type-2 diabetes mellitus. More...

Actinoplanes sp. SE50/110 is known as the wild type producer of the ?-glucosidase inhibitor acarbose, a potent drug used worldwide in the treatment of type-2 diabetes mellitus. Derived strains with increased acarbose yield are used in large scale industrial batch fermentation since 1990. Here, we present the complete genome sequence of Actinoplanes sp. SE50/110, the first publicly available genome of the genus Actinoplanes, comprising various producers of pharmaceutically and economically important secondary metabolites. The genome features a high mean G+C content of 71.32% and consists of one circular chromosome with a size of 9,239,980 bp hosting 8,270 predicted protein coding sequences. Bioinformatic classification of the protein sequences revealed an emphasis on enzymes involved in metabolism including a high number of substrate importers, putatively enabling Actinoplanes sp. SE50/110 to live on various carbon sources in diverse habitats. Full genome phylogenetic analysis revealed a rather distant relation to other sequenced species of the family Micromonosporaceae whereas Actinoplanes utahensis was found to be the closest species based on 16S rDNA comparison alone. The genome hosts several new non-ribosomal peptide synthetases (NRPS), polyketide synthases (PKS) and hybrid clusters, potentially coding for new antibiotics and / or other bioactive compounds. Another key feature of the genome represents the discovery of a functional actinomycete integrative and conjugative element (AICE) which may be used as a system for future genetic modification of Actinoplanes sp. SE50/110 and other Actinoplanes spp. Less...